<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04622254</url>
  </required_header>
  <id_info>
    <org_study_id>M602011070</org_study_id>
    <secondary_id>2019-004113-13</secondary_id>
    <nct_id>NCT04622254</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Crows Feet) in Subjects With Moderate to Severe Upper Facial Lines.</brief_title>
  <acronym>ULTRA II</acronym>
  <official_title>A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study With an Open-label Extension Period to Investigate the Efficacy and Safety of NT 201 in the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merz Pharmaceuticals GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merz Pharmaceuticals GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety and efficacy of NT 201 (active&#xD;
      ingredient: Botulinum (neuro)toxin type A, free from complexing proteins) in the combined&#xD;
      treatment of wrinkles in the upper face: Horizontal Forehead Lines [HFL], Glabellar Frown&#xD;
      Lines [GFL], and Lateral Canthal Lines [LCL]). It is a prospective, randomized, double-blind,&#xD;
      placebo-controlled, multicenter study with a placebo-control main period (MP) followed by an&#xD;
      open-label extension period (OLEX).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 12, 2020</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Actual">June 16, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Glabella Frown Line (GFL) responders at Day 30</measure>
    <time_frame>Day 30</time_frame>
    <description>Merz Aesthetics Scale (MAS - 5-point scale) will be used to identify responders</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of Horizontal Forehead Lines (HFL) responders at Day 30</measure>
    <time_frame>Day 30</time_frame>
    <description>Merz Aesthetics Scale (MAS - 5-point scale) will be used to identify responders</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of Lateral Canthal Lines (LCL) responders at Day 30</measure>
    <time_frame>Day 30</time_frame>
    <description>Merz Aesthetics Scale (MAS - 5-point scale) will be used to identify responders</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with a score of 0 (no) or 1 (mild) on MAS for GFL at maximum contraction as assessed by the investigator at post-baseline visits of MP</measure>
    <time_frame>Week 1, 4, 8, 12, and 16</time_frame>
    <description>Merz Aesthetics Scale (MAS) is a 5-point scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with a score of 0 (no) or 1 (mild) on MAS for HFL at maximum contraction as assessed by the investigator at post-baseline visits of MP</measure>
    <time_frame>Week 1, 4, 8, 12, and 16</time_frame>
    <description>Merz Aesthetics Scale (MAS) is a 5-point scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with a score of 0 (no) or 1 (mild) on MAS for both left and right LCL at maximum contraction as assessed by the investigator at post-baseline visits of MP</measure>
    <time_frame>Week 1, 4, 8, 12, and 16</time_frame>
    <description>Merz Aesthetics Scale (MAS) is a 5-point scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Aesthetic Improvement Scale (GAIS) as assessed by the subject at Day 30 of MP</measure>
    <time_frame>Day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with at least one-grade improvement from baseline to Day 30 of MP on MAS for GFL at maximum contraction as assessed by the investigator</measure>
    <time_frame>Day 30</time_frame>
    <description>Merz Aesthetics Scale (MAS) is a 5-point scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with at least one-grade improvement from baseline to Day 30 of MP on MAS for HFL at maximum contraction as assessed by the investigator</measure>
    <time_frame>Day 30</time_frame>
    <description>Merz Aesthetics Scale (MAS) is a 5-point scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with at least one-grade improvement from baseline to Day 30 of MP on MAS for both left and right LCL at maximum contraction as assessed by the investigator</measure>
    <time_frame>Day 30</time_frame>
    <description>Merz Aesthetics Scale (MAS) is a 5-point scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Aesthetic Improvement Scale (GAIS) as assessed by the investigator at Day 30 of MP</measure>
    <time_frame>Day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of related treatment-emergent adverse events (TEAEs) in the MP</measure>
    <time_frame>Baseline to week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of related TEAEs in the OLEX period</measure>
    <time_frame>Week 16 to 48</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Moderate to Severe Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines)</condition>
  <arm_group>
    <arm_group_label>MP: NT 201 (incobotulinumtoxinA): UFL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intramuscular injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MP: NT201 (incobotulinumtoxinA): LCL, Placebo: GFL/ HFL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intramuscular injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MP: Placebo: UFL</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intramuscular injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OLEX: NT201 (incobotulinumtoxinA): UFL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intramuscular injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NT 201</intervention_name>
    <description>Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).</description>
    <arm_group_label>MP: NT 201 (incobotulinumtoxinA): UFL</arm_group_label>
    <arm_group_label>MP: NT201 (incobotulinumtoxinA): LCL, Placebo: GFL/ HFL</arm_group_label>
    <arm_group_label>OLEX: NT201 (incobotulinumtoxinA): UFL</arm_group_label>
    <other_name>IncobotulinumtoxinA</other_name>
    <other_name>Xeomin</other_name>
    <other_name>Botulinum toxin type A (150 kiloDalton), free from complexing protein</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).</description>
    <arm_group_label>MP: NT201 (incobotulinumtoxinA): LCL, Placebo: GFL/ HFL</arm_group_label>
    <arm_group_label>MP: Placebo: UFL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Outpatients (male or female) 18 years of age or older.&#xD;
&#xD;
          -  Horizontal forehead lines [HFL], glabellar frown lines [GFL], and symmetrical lateral&#xD;
             canthal lines [LCL] of moderate to severe intensity at maximum contraction.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous treatment with botulinum neurotoxin [BoNT] of any serotype in the face within&#xD;
             the last 12 months before injection.&#xD;
&#xD;
          -  Any facial cosmetic procedure within the last 12 months before baseline injection.&#xD;
&#xD;
          -  Previous treatment with any biodegradable filler in the face within the last 12 months&#xD;
             before injection.&#xD;
&#xD;
          -  Any previous insertion of permanent material in the face (regardless of the time&#xD;
             between previous treatment and this study).&#xD;
&#xD;
          -  Any medical condition that may put the subject at increased risk with exposure to&#xD;
             NT201.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Merz Medical Expert</last_name>
    <role>Study Director</role>
    <affiliation>Merz Aesthetics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hautmedizin BadSoden, Merz Investigational Site #0490189</name>
      <address>
        <city>Bad Soden</city>
        <zip>65182</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Privatpraxis fürr Dermatologie und Ästhetische Medizin, Merz Investigational Site #0490306</name>
      <address>
        <city>Berlin</city>
        <zip>10707</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hautarztpraxis Dr. Niesmann &amp; Dr. Othlinghaus, Merz Investigational Site #0490314</name>
      <address>
        <city>Bochum</city>
        <zip>44793</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis für Hautkrankheiten, Merz Investigational Site #0490375</name>
      <address>
        <city>Drensteinfurt</city>
        <zip>48317</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Dr. Hilton &amp; Partner, Merz Investigational Site #0490381</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40212</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universität Hamburg, Institut Für Biologie Und Molekularbiologie, Merz Investigational Site #0490095#</name>
      <address>
        <city>Hamburg</city>
        <zip>20146</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Derma Science, Merz Investigational Site #0490345</name>
      <address>
        <city>Hamburg</city>
        <zip>22609</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Privatklinik Proebstle, Merz Investigational Site #0490284</name>
      <address>
        <city>Mannheim</city>
        <zip>68161</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Privatpraxis für Dermatologie und Ästhetik, Merz Investigational Site #0490371</name>
      <address>
        <city>München</city>
        <zip>80539</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hautarztpraxis München-Neuhausen, Merz Investigational Site #0490372</name>
      <address>
        <city>München</city>
        <zip>80636</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haut- und Lasercentrum, Merz Investigational Site #0490362</name>
      <address>
        <city>Potsdam</city>
        <zip>14467</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CentroDerm, Merz Investigational Site #0490367</name>
      <address>
        <city>Wuppertal</city>
        <zip>42287</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 4, 2020</study_first_submitted>
  <study_first_submitted_qc>November 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2020</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Facies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
    <mesh_term>incobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

